



Preparing and Implementing a National Plan to Eliminate Lymphatic Filariasis



(in countries
where onchocerciasis
is *not co-endemic*)



World Health Organization
Geneva, Switzerland

This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means – electronic, mechanical or other – without prior written permission of WHO.

Ce document n'est pas destiné à être distribué au grand public et tous les droits y afférents sont réservés par l'Organisation Mondiale de la Santé (OMS). Il ne peut être commenté, résumé, cité, reproduit ou traduit, partiellement ou en totalité, sans une autorisation préalable écrite de l'OMS. Aucune partie ne doit être chargée dans un système de recherche documentaire ou diffusée sous quelque forme ou par quelque moyen que ce soit – électronique, mécanique, ou autre – sans une autorisation préalable écrite de l'OMS.

ACKNOWLEDGEMENTS

This Guideline for Programme Managers was developed following an international workshop held in Atlanta, USA in July 1999, organized and hosted by:

- **The World Health Organization**
- **The Centers for Disease Control and Prevention (CDC), Atlanta, USA**
- **The CDC Foundation, Atlanta, USA**

The workshop and subsequent production of the Guideline were supported by an educational grant from:

- **SmithKline Beecham**

with additional travel grant support from:

- **The Arab Fund for Economic and Social Development.**

TABLE OF CONTENTS

1.	INTRODUCTION	1
1.1	Make a commitment to the goal of lymphatic filariasis elimination	2
1.2	Establish the National Task Force (NTF-ELF)	2
1.3	Appoint a national programme manager/coordinator	3
2.	SITUATION ANALYSIS	5-8
2.1	Designate the implementation unit (IU)	5-8
2.2	Assess the distribution of infection and disease	5-8
3.	REVIEW AVAILABLE HUMAN RESOURCES AND INSTITUTIONAL LINKAGES	9
3.1	Within the Ministry of Health	9
3.2	Other ministries	9
3.3	Private sector	10
3.4	Identify the NGOs which can collaborate	10
3.5	Outside the country	10
4.	ASSESS THE SOCIAL AND ECONOMIC IMPACT OF LYMPHATIC FILARIASIS, ESPECIALLY IN DEPRIVED COMMUNITIES	11
5.	DESIGN THE LF ELIMINATION STRATEGIES	13
5.1	Plan for morbidity (disability) control	13
5.2	Plan for interruption of LF transmission through mass drug administration	14-20
5.3	Integrate vector control measures with existing malaria and/or vector control training control programme	20
6.	ESTIMATE DRUG REQUIREMENTS	21
6.1	Design drug procurement and distribution strategy and quality assurance	21
6.2	Calculating requirements and procuring drugs	22-25

TABLE OF CONTENTS

7.	SURVEILLANCE FOR LYMPHATIC FILARIASIS	27
7.1	Background surveillance	27
7.2	Sentinel surveillance	27-30
8.	PLAN INFORMATION AND EDUCATION CAMPAIGN STRATEGIES	31-32
9.	DEFINE A PROGRAMME IMPLEMENTATION INFRASTRUCTURE	33-35
10.	TRAINING AND CAPACITY BUILDING	37-39
11.	PREPARE THE BUDGET FOR THE PELF	41
12.	SET NATIONAL OBJECTIVES AND TARGETS	43-44
13.	IMPLEMENTATION OF ACTIVITIES	45
14.	MONITOR AND SUPERVISE ACTIVITIES AND OUTCOMES	47-48
15.	PERIODIC INDEPENDENT EVALUATIONS	49
	GLOSSARY OF TERMS	51
	REFERENCES	53
Annex 1:	Interview of key informants	55
Annex 2a:	Proforma for recording household members for mass drug administration	56
Annex 2b:	Proforma for recording actual coverage	57
Annex 2c:	Proforma for district compilation of drug coverage and reporting	58
Annex 2d:	Proforma for regional compilation of district-wise drug coverage and reporting	59
Annex 3:	Proforma for recording longitudinal coverage and microfilaraemia rates	60
Annex 4:	Allocation of LF expenses	61-62
Annex 5:	Guideline for monitoring the distribution of co-administered albendazole and DEC during filariasis elimination programmes	63-65

PREFACE

This document is a guideline for managers for planning and establishing a programme for the elimination of lymphatic filariasis.

It is intended for use by national programme managers, programme officials and consultants to the ministries of health in countries where lymphatic filariasis is known, or suspected, to be endemic, but not for use in countries where onchocerciasis is co-endemic with lymphatic filariasis or where the use of diethylcarbamazine citrate (DEC) is contraindicated. National Programme managers of these countries may consult the respective guideline relevant to onchocerciasis co-endemic countries. The epidemiology and clinical manifestations of lymphatic filariasis are not described in this document as extensive information on the subject is readily available elsewhere.

Throughout this document, the term “region” and “district” are used to describe administrative divisions. Each country may have its own nomenclature to describe them. Some comparable terms are listed below:

Region	District
State	Local government area (LGA)
Province	sector

Some countries have advanced into implementation of LF programmes while others have yet to start programmes using the revised recommended strategies. This guide is written in a logical order of programme development and implementation so as to be helpful to programme managers in different situations. The guide is structured so that it may also be used as a reference manual.

The manual will be adapted and changed as the LF community “learns-by-doing”, and all comments and suggestions for changes to the manual are welcome. Suggestions should be addressed to filariasis@who.int. (or, WHO, 1211 Geneva 27, Switzerland, through the relevant WHO Regional Office).

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30479

